UNIVERSAL TECHNICAL INSTITUT (UTI) Fundamental Analysis & Valuation

NYSE:UTI • US9139151040

Current stock price

35.49 USD
-0.84 (-2.31%)
At close:
35.49 USD
0 (0%)
After Hours:

This UTI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. UTI Profitability Analysis

1.1 Basic Checks

  • In the past year UTI was profitable.
  • In the past year UTI had a positive cash flow from operations.
  • UTI had positive earnings in each of the past 5 years.
  • UTI had a positive operating cash flow in each of the past 5 years.
UTI Yearly Net Income VS EBIT VS OCF VS FCFUTI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 6.44%, UTI is in the better half of the industry, outperforming 71.23% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 15.98%, UTI is in the better half of the industry, outperforming 75.34% of the companies in the same industry.
  • UTI's Return On Invested Capital of 8.69% is fine compared to the rest of the industry. UTI outperforms 75.34% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for UTI is significantly below the industry average of 15.48%.
  • The 3 year average ROIC (7.27%) for UTI is below the current ROIC(8.69%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 6.44%
ROE 15.98%
ROIC 8.69%
ROA(3y)4.45%
ROA(5y)3.5%
ROE(3y)11.95%
ROE(5y)9.34%
ROIC(3y)7.27%
ROIC(5y)5.89%
UTI Yearly ROA, ROE, ROICUTI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 -20 -30

1.3 Margins

  • The Profit Margin of UTI (6.28%) is better than 64.38% of its industry peers.
  • In the last couple of years the Profit Margin of UTI has grown nicely.
  • UTI has a Operating Margin of 8.38%. This is in the better half of the industry: UTI outperforms 65.75% of its industry peers.
  • In the last couple of years the Operating Margin of UTI has grown nicely.
  • UTI has a Gross Margin of 49.62%. This is comparable to the rest of the industry: UTI outperforms 57.53% of its industry peers.
  • In the last couple of years the Gross Margin of UTI has declined.
Industry RankSector Rank
OM 8.38%
PM (TTM) 6.28%
GM 49.62%
OM growth 3Y17.03%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5Y53.06%
GM growth 3Y-13.36%
GM growth 5Y-8.21%
UTI Yearly Profit, Operating, Gross MarginsUTI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. UTI Health Analysis

2.1 Basic Checks

  • UTI has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, UTI has more shares outstanding
  • Compared to 5 years ago, UTI has more shares outstanding
  • UTI has a better debt/assets ratio than last year.
UTI Yearly Shares OutstandingUTI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
UTI Yearly Total Debt VS Total AssetsUTI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • An Altman-Z score of 3.90 indicates that UTI is not in any danger for bankruptcy at the moment.
  • UTI's Altman-Z score of 3.90 is fine compared to the rest of the industry. UTI outperforms 78.08% of its industry peers.
  • The Debt to FCF ratio of UTI is 6.28, which is on the high side as it means it would take UTI, 6.28 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 6.28, UTI is in the better half of the industry, outperforming 69.86% of the companies in the same industry.
  • A Debt/Equity ratio of 0.29 indicates that UTI is not too dependend on debt financing.
  • UTI has a Debt to Equity ratio of 0.29. This is comparable to the rest of the industry: UTI outperforms 56.16% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF 6.28
Altman-Z 3.9
ROIC/WACC1
WACC8.7%
UTI Yearly LT Debt VS Equity VS FCFUTI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • UTI has a Current Ratio of 1.14. This is a normal value and indicates that UTI is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.14, UTI is in line with its industry, outperforming 43.84% of the companies in the same industry.
  • UTI has a Quick Ratio of 1.14. This is a normal value and indicates that UTI is financially healthy and should not expect problems in meeting its short term obligations.
  • UTI's Quick ratio of 1.14 is in line compared to the rest of the industry. UTI outperforms 46.58% of its industry peers.
Industry RankSector Rank
Current Ratio 1.14
Quick Ratio 1.14
UTI Yearly Current Assets VS Current LiabilitesUTI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. UTI Growth Analysis

3.1 Past

  • UTI shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
  • UTI shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 65.96% yearly.
  • The Revenue has grown by 12.59% in the past year. This is quite good.
  • The Revenue has been growing by 22.67% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)0%
EPS 3Y3.11%
EPS 5Y65.96%
EPS Q2Q%-42.5%
Revenue 1Y (TTM)12.59%
Revenue growth 3Y25.89%
Revenue growth 5Y22.67%
Sales Q2Q%9.64%

3.2 Future

  • Based on estimates for the next years, UTI will show a small growth in Earnings Per Share. The EPS will grow by 5.89% on average per year.
  • UTI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.84% yearly.
EPS Next Y-31.19%
EPS Next 2Y-10.6%
EPS Next 3Y5.89%
EPS Next 5YN/A
Revenue Next Year9.48%
Revenue Next 2Y8.9%
Revenue Next 3Y8.84%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
UTI Yearly Revenue VS EstimatesUTI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M 800M 1B
UTI Yearly EPS VS EstimatesUTI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 1 -1

More info and screens

Find the best growth stocksShow best growing peers

2

4. UTI Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 36.59, the valuation of UTI can be described as expensive.
  • UTI's Price/Earnings is on the same level as the industry average.
  • When comparing the Price/Earnings ratio of UTI to the average of the S&P500 Index (27.42), we can say UTI is valued slightly more expensively.
  • A Price/Forward Earnings ratio of 38.95 indicates a quite expensive valuation of UTI.
  • UTI's Price/Forward Earnings ratio is in line with the industry average.
  • When comparing the Price/Forward Earnings ratio of UTI to the average of the S&P500 Index (22.29), we can say UTI is valued expensively.
Industry RankSector Rank
PE 36.59
Fwd PE 38.95
UTI Price Earnings VS Forward Price EarningsUTI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • UTI's Enterprise Value to EBITDA ratio is in line with the industry average.
  • UTI's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 120.99
EV/EBITDA 17.26
UTI Per share dataUTI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • UTI has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.55
EPS Next 2Y-10.6%
EPS Next 3Y5.89%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. UTI Dividend Analysis

5.1 Amount

  • No dividends for UTI!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

UTI Fundamentals: All Metrics, Ratios and Statistics

UNIVERSAL TECHNICAL INSTITUT

NYSE:UTI (4/24/2026, 8:12:47 PM)

After market: 35.49 0 (0%)

35.49

-0.84 (-2.31%)

Chartmill FA Rating
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)02-04
Earnings (Next)05-06
Inst Owners96.88%
Inst Owner Change3.67%
Ins Owners2.49%
Ins Owner Change3.2%
Market Cap1.95B
Revenue(TTM)855.03M
Net Income(TTM)53.69M
Analysts81.82
Price Target38.42 (8.26%)
Short Float %6.76%
Short Ratio4.54
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.03
Dividend Growth(5Y)-34.43%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.57%
Min EPS beat(2)28.91%
Max EPS beat(2)66.22%
EPS beat(4)4
Avg EPS beat(4)59.42%
Min EPS beat(4)28.91%
Max EPS beat(4)73.27%
EPS beat(8)7
Avg EPS beat(8)48.68%
EPS beat(12)11
Avg EPS beat(12)85.96%
EPS beat(16)14
Avg EPS beat(16)183.11%
Revenue beat(2)2
Avg Revenue beat(2)0.64%
Min Revenue beat(2)0.47%
Max Revenue beat(2)0.82%
Revenue beat(4)4
Avg Revenue beat(4)1.74%
Min Revenue beat(4)0.47%
Max Revenue beat(4)4.51%
Revenue beat(8)8
Avg Revenue beat(8)2.01%
Revenue beat(12)12
Avg Revenue beat(12)2.35%
Revenue beat(16)15
Avg Revenue beat(16)2.9%
PT rev (1m)0%
PT rev (3m)0.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-103.86%
EPS NY rev (1m)0%
EPS NY rev (3m)0.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.21%
Valuation
Industry RankSector Rank
PE 36.59
Fwd PE 38.95
P/S 2.28
P/FCF 120.99
P/OCF 25.21
P/B 5.81
P/tB 6.82
EV/EBITDA 17.26
EPS(TTM)0.97
EY2.73%
EPS(NY)0.91
Fwd EY2.57%
FCF(TTM)0.29
FCFY0.83%
OCF(TTM)1.41
OCFY3.97%
SpS15.54
BVpS6.11
TBVpS5.21
PEG (NY)N/A
PEG (5Y)0.55
Graham Number11.5432 (-67.47%)
Profitability
Industry RankSector Rank
ROA 6.44%
ROE 15.98%
ROCE 11.63%
ROIC 8.69%
ROICexc 11.82%
ROICexgc 13.27%
OM 8.38%
PM (TTM) 6.28%
GM 49.62%
FCFM 1.89%
ROA(3y)4.45%
ROA(5y)3.5%
ROE(3y)11.95%
ROE(5y)9.34%
ROIC(3y)7.27%
ROIC(5y)5.89%
ROICexc(3y)10.21%
ROICexc(5y)8.25%
ROICexgc(3y)11.54%
ROICexgc(5y)9.21%
ROCE(3y)9.72%
ROCE(5y)7.88%
ROICexgc growth 3Y34.26%
ROICexgc growth 5YN/A
ROICexc growth 3Y33.76%
ROICexc growth 5YN/A
OM growth 3Y17.03%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5Y53.06%
GM growth 3Y-13.36%
GM growth 5Y-8.21%
F-Score7
Asset Turnover1.03
Health
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF 6.28
Debt/EBITDA 0.93
Cap/Depr 181.06%
Cap/Sales 7.17%
Interest Coverage 13.88
Cash Conversion 73.39%
Profit Quality 30.06%
Current Ratio 1.14
Quick Ratio 1.14
Altman-Z 3.9
F-Score7
WACC8.7%
ROIC/WACC1
Cap/Depr(3y)145.01%
Cap/Depr(5y)268.95%
Cap/Sales(3y)5.89%
Cap/Sales(5y)11.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y3.11%
EPS 5Y65.96%
EPS Q2Q%-42.5%
EPS Next Y-31.19%
EPS Next 2Y-10.6%
EPS Next 3Y5.89%
EPS Next 5YN/A
Revenue 1Y (TTM)12.59%
Revenue growth 3Y25.89%
Revenue growth 5Y22.67%
Sales Q2Q%9.64%
Revenue Next Year9.48%
Revenue Next 2Y8.9%
Revenue Next 3Y8.84%
Revenue Next 5YN/A
EBIT growth 1Y-0.64%
EBIT growth 3Y47.33%
EBIT growth 5YN/A
EBIT Next Year46.18%
EBIT Next 3Y27.41%
EBIT Next 5YN/A
FCF growth 1Y371.76%
FCF growth 3YN/A
FCF growth 5Y99.08%
OCF growth 1Y35.47%
OCF growth 3Y28.35%
OCF growth 5Y54.57%

UNIVERSAL TECHNICAL INSTITUT / UTI Fundamental Analysis FAQ

What is the fundamental rating for UTI stock?

ChartMill assigns a fundamental rating of 5 / 10 to UTI.


What is the valuation status for UTI stock?

ChartMill assigns a valuation rating of 2 / 10 to UNIVERSAL TECHNICAL INSTITUT (UTI). This can be considered as Overvalued.


What is the profitability of UTI stock?

UNIVERSAL TECHNICAL INSTITUT (UTI) has a profitability rating of 7 / 10.


What is the valuation of UNIVERSAL TECHNICAL INSTITUT based on its PE and PB ratios?

The Price/Earnings (PE) ratio for UNIVERSAL TECHNICAL INSTITUT (UTI) is 36.59 and the Price/Book (PB) ratio is 5.81.


Can you provide the expected EPS growth for UTI stock?

The Earnings per Share (EPS) of UNIVERSAL TECHNICAL INSTITUT (UTI) is expected to decline by -31.19% in the next year.